eod-gt8 60mer
Vaccineexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 15, 2018 (NCT03547245)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05414786 | Phase 1 | May 26, 2022 | Center for Family Health Research (CFHR), International AIDS Vaccine Initiative, Moderna Therapeutics, Tembisa Hospital, South Africa |
| NCT05001373 | Phase 1 | Oct 15, 2021 | Emory University, George Washington University, International AIDS Vaccine Initiative, Moderna Therapeutics, University of Texas, San Antonio, University of Washington |
| NCT03547245 | Phase 1 | Jun 15, 2018 | George Washington University, International AIDS Vaccine Initiative, University of Washington |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| International AIDS Vaccine Initiative | Academic/Hospital | 3 | 3 | 1 | 2018 |
| George Washington University | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Moderna Therapeutics | For profit | 2 | 0 | 1 | 2021 |
| University of Washington | Academic/Hospital | 2 | 0 | 1 | 2018 |
| Center for Family Health Research (CFHR) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Tembisa Hospital, South Africa | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 0 | 1 | 2021 |
8 organizations
Page 1 / 1